Short Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Grows By 486.2%

RedHill Biopharma Ltd. (NASDAQ:RDHL) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 34,000 shares, an increase of 486.2% from the February 13th total of 5,800 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average trading volume of 54,100 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of RedHill Biopharma in a research report on Thursday. They issued a “hold” rating on the stock.

RedHill Biopharma Stock Up 1.8 %

Shares of NASDAQ RDHL opened at $2.84 on Thursday. RedHill Biopharma has a 12 month low of $2.53 and a 12 month high of $20.28. The business’s 50 day moving average is $5.21 and its two-hundred day moving average is $7.11.

Institutional Trading of RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC bought a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is currently owned by hedge funds and other institutional investors.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.